The global Icatibant Acetate API market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Icatibant Acetate is the acetate salt form of icatibant, an antagonist of the human bradykinin B2 receptor (B2R), that can be used for the treatment of hereditary angioedema (HAE). Upon administration, icatibant targets and binds to B2R, thereby preventing bradykinin from binding to the B2R. This may prevent bradykinin/B2R-mediated vasodilation, the resulting increase in vascular permeability, and the swelling, inflammation, and pain associated with HAE. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.

United States market for Icatibant Acetate API is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Icatibant Acetate API is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Icatibant Acetate API is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Icatibant Acetate API players cover Dr. Reddy’s Laboratories Ltd., ChemWerth Inc, Bachem AG, Biophore India Pharmaceuticals Pvt. Ltd., Tecoland Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Icatibant Acetate API Industry Forecast” looks at past sales and reviews total world Icatibant Acetate API sales in 2024, providing a comprehensive analysis by region and market sector of projected Icatibant Acetate API sales for 2025 through 2031. With Icatibant Acetate API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Icatibant Acetate API industry.

This Insight Report provides a comprehensive analysis of the global Icatibant Acetate API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Icatibant Acetate API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Icatibant Acetate API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Icatibant Acetate API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Icatibant Acetate API.

This report presents a comprehensive overview, market shares, and growth opportunities of Icatibant Acetate API market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    Purity≥98%
    Purity